|
Name |
Prehelminthosporolactone
|
Molecular Formula | C15H22O2 | |
IUPAC Name* |
(1R,3R,7S,8S,9R)-1-methyl-2-methylidene-9-propan-2-yl-5-oxatricyclo[5.4.0.03,8]undecan-4-one
|
|
SMILES |
CC(C)[C@H]1CC[C@@]2([C@@H]3[C@H]1[C@H](C2=C)C(=O)OC3)C
|
|
InChI |
InChI=1S/C15H22O2/c1-8(2)10-5-6-15(4)9(3)12-13(10)11(15)7-17-14(12)16/h8,10-13H,3,5-7H2,1-2,4H3/t10-,11+,12+,13+,15+/m1/s1
|
|
InChIKey |
YRJUYCPYOZTNDX-MCZMQQNQSA-N
|
|
Synonyms |
Prehelminthosporolactone; 118101-72-7; (1R,3R,7S,8S,9R)-1-methyl-2-methylidene-9-propan-2-yl-5-oxatricyclo[5.4.0.03,8]undecan-4-one
|
|
CAS | NA | |
PubChem CID | 14165716 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 234.33 | ALogp: | 3.6 |
HBD: | 0 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 26.3 | Aromatic Rings: | 3 |
Heavy Atoms: | 17 | QED Weighted: | 0.509 |
Caco-2 Permeability: | -4.608 | MDCK Permeability: | 0.00002440 |
Pgp-inhibitor: | 0.915 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.947 |
30% Bioavailability (F30%): | 0.887 |
Blood-Brain-Barrier Penetration (BBB): | 0.059 | Plasma Protein Binding (PPB): | 96.56% |
Volume Distribution (VD): | 0.775 | Fu: | 4.32% |
CYP1A2-inhibitor: | 0.927 | CYP1A2-substrate: | 0.796 |
CYP2C19-inhibitor: | 0.645 | CYP2C19-substrate: | 0.899 |
CYP2C9-inhibitor: | 0.661 | CYP2C9-substrate: | 0.062 |
CYP2D6-inhibitor: | 0.226 | CYP2D6-substrate: | 0.1 |
CYP3A4-inhibitor: | 0.671 | CYP3A4-substrate: | 0.66 |
Clearance (CL): | 10.878 | Half-life (T1/2): | 0.318 |
hERG Blockers: | 0.102 | Human Hepatotoxicity (H-HT): | 0.17 |
Drug-inuced Liver Injury (DILI): | 0.484 | AMES Toxicity: | 0.053 |
Rat Oral Acute Toxicity: | 0.404 | Maximum Recommended Daily Dose: | 0.183 |
Skin Sensitization: | 0.805 | Carcinogencity: | 0.36 |
Eye Corrosion: | 0.932 | Eye Irritation: | 0.904 |
Respiratory Toxicity: | 0.948 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004835 | 1.000 | D04CSZ | 0.271 | ||||
ENC001293 | 0.607 | D0A2AJ | 0.247 | ||||
ENC001878 | 0.586 | D0D2VS | 0.244 | ||||
ENC005456 | 0.557 | D0S3WH | 0.244 | ||||
ENC000976 | 0.463 | D04VIS | 0.239 | ||||
ENC002553 | 0.450 | D0K0EK | 0.235 | ||||
ENC003488 | 0.444 | D0K7LU | 0.234 | ||||
ENC000535 | 0.403 | D0U3GL | 0.230 | ||||
ENC001140 | 0.381 | D0H1QY | 0.230 | ||||
ENC003050 | 0.379 | D0G8BV | 0.222 |